Segmental allergen challenge
PreclinicalBiologic
Segmental allergen challenge is one of 32 biologic programs targeting Allergic Disease. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Allergic Disease
#DrugCompanyPhaseTrials
1Taxol
TevaApproved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Clarinex
OOrganon and Co
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Alvesco
AAzurity Pharmaceuticals
Approved
Foradil
ViatrisApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Wisconsin, Madison